Evaluation of a blockbuster heart failure medication

Charles River Associates medicine on money

On behalf of a plaintiff for a blockbuster heart failure fixed-dose combination medication, CRA was retained to assess the commercial success of the product and the nexus between the success and the patents-in-suit. CRA consultants assessed the product’s sales, sales growth, and profitability in a competitive environment that included numerous alternative treatments. Consideration of clinical research, clinical guidelines, and marketing literature supported a conclusion of commercial success attributable to the patents-in-suit. Finally, CRA consultants also considered whether earlier plaintiff patents deterred and “blocked” competitor research into the product in the context of typical drug development timelines.

Meet our team

Additional contributors